Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain

Psychopharmacology

Volumn 144, Issue 3, 1999, Pages 286-294

  Timmerman, W ^a   Heijmen, M ^b   Westerink, B H C ^b   Bruggeman, R ^a   Den Boer, J A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Medicinal Chemistry ^*  (Netherlands)

Author keywords

Antipsychotic; Chronic treatment; Extrapyramidal side effects; Substantia nigra reticulata

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE;

ARTICLE; BRAIN MAPPING; BRAIN NERVE CELL; BRAIN REGION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CLOZAPINE; HALOPERIDOL; MALE; NEURONS; PIRENZEPINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 0033017232     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051006     Document Type: Article

References (38)

1. Alexander GE, DeLong MR, Strick PL (1987) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357-381
2. Ashby ChR, Wang RY (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24: 349-394
3. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996) Olanzapine HGAD Study Group: olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-118
4. Bruggeman R, Westerink BHC, Timmerman W (1997) Effects of risperidone, clozapine and haloperidol on extracellular recordings of SNR neurons of the rat brain. Eur J Pharmacol 324:49-56
5. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore ND, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
6. Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. Trends Neurol Sci 13:277-281
7. Chevalier G, Deniau JM, Theirry AM, Feger J (1981) The nigrotectal pathway. An electrophysiological reinvestigation in the rat. Brain Res 213:253-263
8. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviour. Psychopharmacology 120:67-74
9. DeLong M (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurol Sci 13:281-308
10. Deniau JM, Menetrey A, Thierry AM (1994) Indirect nucleus accumbens input to the prefrontal cortex via the substantia nigra pars reticulata: a combined anatomical and electrophysiological study in the rat. Neuroscience 61:533-545
11. Fink H, Morgenstern R, Oetssner W (1984) Clozapine - a serotonin antagonist? Pharmacol Biochem Behav 20:513-517
12. Fulton B, Goa KL (1997) Olanzapine, a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298
13. Gale K (1980) Chronic blockade of DA receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283:569-570
14. Grace AA, Bunney BS (1979) Paradoxical GABA excitation of nigral dopaminergic cells: indirect mediation through reticular inhibitory neurons. Eur J Pharmacol 59:211-218
15. Gunne LM, Haggstrom JE (1983) Reduction of nigral glutamic acid decarboxylase in rats with antipsychotic-induced oral dyskinesia. Psychopharmacology 81:191-194
16. Guyenet PG, Aghajanian GK (1978) Antidromic identification of DA-ergic and other output neurons of the rat substantia nigra. Brain Res 150:69-84
17. Hikosaka O, Wurtz RH (1983) Visual and oculomotor functions of monkey substantia nigra pars reticulata. I Relation of substantia nigra to superior colliculus. J Neurophysiol 49: 1285-1301
18. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133
19. Itoh M (1983) Effect of haloperidol on glutamate decarboxylase activity in discrete brain areas of the rat. Psychopharmacology 79:169-172
20. Leysen JE, Gommeren W, Eens A, De Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
21. 2 receptors. Psychopharmacology 112:S40-S54
22. Lynd-Balta E, Haber SN (1994) Primate striato-nigral projections; a comparison of the sensorimotor-related striatum and the ventral striatum. J Comp Neurol 345:562-578
23. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
24. Meltzer HY (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18:515-542
25. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioural pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
26. Morelli M, Porceddu ML, Imperato A, DiChiara G (1981) Role of substantia nigra pars reticulata neurons in the expression of antipsychotic-induced catalepsy. Brain Res 217:375-379
27. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychol 152:1444-1449
28. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology 110:265-272
29. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7
30. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates, 1st edition. Academic Press, London
31. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-1410
32. Rupniak NMJ, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden CD (1985) Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol 34: 2755-2763
33. See RE, Aravagiri M, Ellison GD (1989) Chronic antipsychotic treatment in rats produces persisting changes in GABA-A and dopamine D-2, but not dopamine D-1 receptors. Life Sci 44:229-236
34. 1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Exp Neurol 127:62-69
35. Skarfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289-294
36. Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-104
37. Tollefson GD, Beasley ChM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophrenifrom disorders: results of an international collaboration. Am J Psychol 154:457-465
38. White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057